uploads/2017/11/Chart-04-2-1.jpg

How AstraZeneca’s Growth Platforms Performed in 3Q17

By

Updated

AstraZeneca’s growth platforms

As we’ve already seen, AstraZeneca’s (AZN) growth platforms include new products for the Cardiovascular and Metabolic Diseases (or CVMD) segment, including Brilinta, Bydureon, Byetta, Farxiga, and Onglyza; new products for the Oncology segment, including Imfinzi, Iressa, Lynparza, and Tagrisso; and products in the Respiratory segment. It also includes revenues from emerging markets and Japan.

The above chart shows revenues for growth platforms in 3Q17.

Article continues below advertisement

Performance of growth platforms

Below are the performances of each category in the growth platform during 3Q17:

  • Emerging markets include revenues from Brazil, China, India, Mexico, Russia, and Turkey. Revenues from emerging markets reported a 10% growth at constant exchange rates to $1.5 billion during 3Q17. In emerging markets, Chinese revenues increased 14% at constant exchange rates to $723 million, while other emerging markets reported revenue growth of 7% at constant exchange rates to $792 million.
  • Japanese markets reported 4% growth in revenues at constant exchange rates to $578 million during 3Q17, driven by the strong performances of Tagrisso and Symbicort.
  • For growth platforms, new CVMD products include cardiovascular drug Brilinta and diabetes drugs Bydureon, Byetta, Onglyza, and Farxiga. New CVMD products reported 7% growth in revenues at constant exchange rates to $873 million during 3Q17, driven by the strong performances of Brilinta and Farxiga.
  • The Respiratory segment reported a 2% fall in revenues at constant exchange rates to ~$1.1 billion during 3Q17, driven by lower sales of Symbicort and Tudorza/Eklira, substantially offset by the strong performances of Pulmicort, Daliresp, and Duaklir.
  • For growth platforms, new products for the Oncology segment include Calquence and Imfinzi and US sales for Iressa, Lynparza, and Tagrisso. New Oncology products reported 73% growth in revenues at constant exchange rates to $339 million during 3Q17, driven by strong sales of Tagrisso and new products Calquence and Imfinzi.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 5.6% of its total assets in AstraZeneca (AZN). PPH also holds 5.3% in Pfizer (PFE), 5.4% in Mylan (MYL), and 5.2% in Bristol-Myers Squibb (BMY).

Advertisement

More From Market Realist